Tango Therapeutics, a clinical-stage biotechnology company, announces the retirement of CEO Dr. Barbara Weber.
Dr. Weber will become Executive Chair of the board, succeeded by Dr. Malte Peters as President and CEO.
Dr. Peters, a distinguished leader, brings extensive clinical development experience to drive the company's growth.
CEO Transition
Dr. Barbara Weber retires as CEO, becoming Executive Chair; Dr. Malte Peters appointed as President and CEO.
Leadership Expertise
Dr. Peters' experience in late-stage clinical development and strategic vision will drive Tango's growth.
Clinical Milestones
Renewed guidance includes upcoming combination trials with vopimetostat.
- Dr. Barbara Weber's retirement marks a significant transition in Tango's leadership.
- Dr. Malte Peters' appointment brings a wealth of clinical development experience to lead Tango's future growth.
- The company's focus on upcoming clinical trials with vopimetostat reflects its commitment to advancing precision cancer medicines.
Tango Therapeutics anticipates continued growth under Dr. Malte Peters' leadership as they pursue their mission to improve outcomes for cancer patients.